USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ACPHARIS
Address:
160 N MILL ST
HOLLISTON, MA 01746-1042
Phone:
N/A
URL:
EIN:
262841221
DUNS:
830023755
Number of Employees:
2
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $374,999.00 2
STTR Phase I $202,953.00 2

Award List:

High-throughput portable software for fragment-based drug design

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$98,055.00
Agency:
HHS
Principal Investigator:
Sandor Vajda – 617-353-4757
Research Institution:
BOSTON UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Fragment-based drug design (FBDD) is a combinatorial approach in which individual fragments binding to regions of the target site are selected from a fragment library, and then combined to form potential lead compounds.Interest in this approach has significantly… More

GPU Accelerated Protein Docking Software with Flexible Refinement

Award Year / Program / Phase:
2012 / STTR / Phase I
Award Amount:
$104,898.00
Agency:
HHS
Principal Investigator:
Martin C. Herbordt – 617-353-9850
Research Institution:
BOSTON UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Protein-protein interactions are involved at multiple points in virtually all biological pathways. Understanding such interactions is also important for the design of biologics that can target extracellular receptors with high affinity and specificity. Since… More

SOFTWARE FOR MODELING AND OPTIMIZATION OF PROTEIN THERAPEUTICS

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$149,999.00
Agency:
HHS
Principal Investigator:
David R. Hall – (703) 217-9531
Abstract:
DESCRIPTION: Therapeutic proteins, including antibodies and other scaffolds such as DARPins and affibodies have become important drugs to treat cancer, infectious and cardiovascular diseases, arthritis, inflammation and immune disorders, and are expected to drive further growth of the biotechnology… More

Software for Fragment-based Design of Covalent Inhibitors

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$225,000.00
Agency:
HHS
Principal Investigator:
David R. Hall – 703-217-9531
Abstract:
DESCRIPTION (provided by applicant): Covalent drugs represent a significant portion of current pharmaceuticals, with the top 26 having sales of over 30B in the US alone. While in the past target-directed drug discovery projects rarely pursued covalent binders due to safety concerns, the industry is… More